Refined high-content imaging-based phenotypic drug screening in zebrafish xenografts.
Npj Precision Oncology
Sturtzel, C C; Grissenberger, S S; Bozatzi, P P; Scheuringer, E E; Wenninger-Weinzierl, A A; Zajec, Z Z; Dernovšek, J J; Pascoal, S S; Gehl, V V; Kutsch, A A; Granig, A A; Rifatbegovic, F F; Carre, M M; Lang, A A; Valtingojer, I I; Moll, J J; Lötsch, D D; Erhart, F F; Widhalm, G G; Surdez, D D; Delattre, O O; André, N N; Stampfl, J J; Tomašič, T T; Taschner-Mandl, S S; Distel, M M
Circulating tumor DNA reveals mechanisms of lorlatinib resistance in patients with relapsed/refractory ALK-driven neuroblastoma.
Nature Communications
Berko, Esther R ER; Witek, Gabriela M GM; Matkar, Smita S; Petrova, Zaritza O ZO; Wu, Megan A MA; Smith, Courtney M CM; Daniels, Alex A; Kalna, Joshua J; Kennedy, Annie A; Gostuski, Ivan I; Casey, Colleen C; Krytska, Kateryna K; Gerelus, Mark M; Pavlick, Dean D; Ghazarian, Susan S; Park, Julie R JR; Marachelian, Araz A; Maris, John M JM; Goldsmith, Kelly C KC; Radhakrishnan, Ravi R; Lemmon, Mark A MA; Mossé, Yaël P YP
Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results.
Nature Medicine
Goldsmith, Kelly C KC; Park, Julie R JR; Kayser, Kimberly K; Malvar, Jemily J; Chi, Yueh-Yun YY; Groshen, Susan G SG; Villablanca, Judith G JG; Krytska, Kateryna K; Lai, Lillian M LM; Acharya, Patricia T PT; Goodarzian, Fariba F; Pawel, Bruce B; Shimada, Hiroyuki H; Ghazarian, Susan S; States, Lisa L; Marshall, Lynley L; Chesler, Louis L; Granger, Meaghan M; Desai, Ami V AV; Mody, Rajen R; Morgenstern, Daniel A DA; Shusterman, Suzanne S; Macy, Margaret E ME; Pinto, Navin N; Schleiermacher, Gudrun G; Vo, Kieuhoa K; Thurm, Holger C HC; Chen, Joseph J; Liyanage, Marlon M; Peltz, Gerson G; Matthay, Katherine K KK; Berko, Esther R ER; Maris, John M JM; Marachelian, Araz A; Mossé, Yael P YP
Neuroblastoma arises in early fetal development and its evolutionary duration predicts outcome.
Nature Genetics
Körber, Verena V; Stainczyk, Sabine A SA; Kurilov, Roma R; Henrich, Kai-Oliver KO; Hero, Barbara B; Brors, Benedikt B; Westermann, Frank F; Höfer, Thomas T
Segmental chromosomal aberrations as the poor prognostic factor in children over 18 months with stage 3 neuroblastoma without MYCN amplification.
Frontiers In Oncology
Wieczorek, Aleksandra A; Szewczyk, Katarzyna K; Klekawka, Tomasz T; Stefanowicz, Joanna J; Ussowicz, Marek M; Drabik, Grazyna G; Pawinska-Wasikowska, Katarzyna K; Balwierz, Walentyna W
Genomic ALK alterations in primary and relapsed neuroblastoma.
British Journal Of Cancer
Rosswog, Carolina C; Fassunke, Jana J; Ernst, Angela A; Schömig-Markiefka, Birgid B; Merkelbach-Bruse, Sabine S; Bartenhagen, Christoph C; Cartolano, Maria M; Ackermann, Sandra S; Theissen, Jessica J; Blattner-Johnson, Mirjam M; Jones, Barbara B; Schramm, Kathrin K; Altmüller, Janine J; Nürnberg, Peter P; Ortmann, Monika M; Berthold, Frank F; Peifer, Martin M; Büttner, Reinhard R; Westermann, Frank F; Schulte, Johannes H JH; Simon, Thorsten T; Hero, Barbara B; Fischer, Matthias M
Silibinin Overcomes EMT-Driven Lung Cancer Resistance to New-Generation ALK Inhibitors.
Cancers
Verdura, Sara S; Encinar, Jose Antonio JA; Teixidor, Eduard E; Segura-Carretero, Antonio A; Micol, Vicente V; Cuyàs, Elisabet E; Bosch-Barrera, Joaquim J; Menendez, Javier A JA
Primary resistance to first- and second-generation ALK inhibitors in a non-small cell lung cancer patient with coexisting ALK rearrangement and an ALK F1174L-cis-S1189C de novo mutation: A case report.
Biochemical and structural basis for differential inhibitor sensitivity of EGFR with distinct exon 19 mutations.
Nature Communications
van Alderwerelt van Rosenburgh, Iris K IK; Lu, David M DM; Grant, Michael J MJ; Stayrook, Steven E SE; Phadke, Manali M; Walther, Zenta Z; Goldberg, Sarah B SB; Politi, Katerina K; Lemmon, Mark A MA; Ashtekar, Kumar D KD; Tsutsui, Yuko Y
A comprehensive next generation sequencing tissue assay for Asian-prevalent cancers-Analytical validation and performance evaluation with clinical samples.
MHY4571, a novel diarylcyclohexanone derivative, exerts anti-cancer activity by regulating the PKA-cAMP-response element-binding protein pathway in squamous cell lung cancer.
Experimental Hematology & Oncology
Chung, Jae Heun JH; Choi, Ho Jung HJ; Kang, Yong Jung YJ; Kim, Yun Seong YS; Lee, Sang-Yull SY; Kwon, Ryuk Jun RJ; Jeong, Han-Sol HS; Park, Su-Jung SJ; Jeong, Yeongmu Y; Kang, Dongwan D; Ko, Jeongin J; Noh, SangGyun S; Chung, Hae Young HY; Moon, Hyung Ryong HR; Yoon, Seong Hoon SH
Lorlatinib and compound mutations in ALK+ large-cell neuroendocrine lung carcinoma: a case report.
Cold Spring Harbor Molecular Case Studies
Wiedemann, Christiane C; Kazdal, Daniel D; Cvetkovic, Jelena J; Kunz, Julia J; Fisch, David D; Kirchner, Martina M; Kriegsmann, Mark M; Sültmann, Holger H; Heussel, Claus-Peter CP; Bischoff, Helge H; Thomas, Michael M; Stenzinger, Albrecht A; Christopoulos, Petros P
Loss of ALK hotspot mutations in relapsed neuroblastoma.
Genes, Chromosomes & Cancer
Allinson, Lisa M LM; Potts, Aaron A; Goodman, Angharad A; Bown, Nick N; Bashton, Matthew M; Thompson, Dean D; Basta, Nermine O NO; Gabriel, Alem S AS; McCorkindale, Michael M; Ng, Antony A; McNally, Richard J Q RJQ; Tweddle, Deborah A DA
Pugh, Trevor J TJ; Bell, Jonathan L JL; Bruce, Jeff P JP; Doherty, Gary J GJ; Galvin, Matthew M; Green, Michelle F MF; Hunter-Zinck, Haley H; Kumari, Priti P; Lenoue-Newton, Michele L ML; Li, Marilyn M MM; Lindsay, James J; Mazor, Tali T; Ovalle, Andrea A; Sammut, Stephen-John SJ; Schultz, Nikolaus N; Yu, Thomas V TV; Sweeney, Shawn M SM; Bernard, Brady B; ,
The Change in Paradigm for NSCLC Patients with EML4-ALK Translocation.
International Journal Of Molecular Sciences
Bearz, Alessandra A; De Carlo, Elisa E; Del Conte, Alessandro A; Spina, Michele M; Da Ros, Valentina V; Bertoli, Elisa E; Revelant, Alberto A; Stanzione, Brigida B; Tirelli, Umberto U
Longitudinal monitoring by next-generation sequencing of plasma cell-free DNA in ALK rearranged NSCLC patients treated with ALK tyrosine kinase inhibitors.
Cancer Medicine
Kwon, Minsuk M; Ku, Bo Mi BM; Olsen, Steve S; Park, Sehhoon S; Lefterova, Martina M; Odegaard, Justin J; Jung, Hyun-Ae HA; Sun, Jong-Mu JM; Lee, Se-Hoon SH; Ahn, Jin Seok JS; Park, Keunchil K; Ahn, Myung-Ju MJ
Brigatinib for Pretreated, ALK-Positive, Advanced Non-Small-Cell Lung Cancers: Long-Term Follow-Up and Focus on Post-Brigatinib Lorlatinib Efficacy in the Multicenter, Real-World BrigALK2 Study.
Cancers
Descourt, Renaud R; Pérol, Maurice M; Rousseau-Bussac, Gaëlle G; Planchard, David D; Mennecier, Bertrand B; Wislez, Marie M; Cadranel, Jacques J; Cortot, Alexis Benjamin AB; Guisier, Florian F; Galland, Loïck L; Do, Pascal P; Schott, Roland R; Dansin, Éric É; Arrondeau, Jennifer J; Auliac, Jean-Bernard JB; Geier, Margaux M; Chouaïd, Christos C